PET/CT在霍奇金淋巴瘤初始分期中的意义：临床试验以外的经验
The Significance of PET/CT in the Initial Staging of Hodgkin Lymphoma: Experience Outside Clinical Trials.
作者信息
Angelopoulou Maria K, Mosa Eftychia, Pangalis Gerassimos A, Rondogianni Phoivi, Chatziioannou Sofia, Prassopoulos Vassilios, Moschogianni Maria, Tsirkinidis Pantelis, Asimakopoulos John V, Konstantinou Iliana, Tsourouflis Gerasimos, Sachanas Sotirios, Yiakoumis Xanthi, Boutsikas George, Arapaki Maria, Gainaru Gabriella, Kyrtsonis Marie-Christine, Siakantaris Marina P, Datseris Ioannis, Panayiotidis Panagiotis, Konstantopoulos Kostas, Vassilakopoulos Theodoros P
机构信息
Department of Hematology, Laikon General Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
Department of Hematology, Laikon General Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece.
出版信息
Anticancer Res. 2017 Oct;37(10):5727-5736. doi: 10.21873/anticanres.12011.
AIM
To examine the real-life impact of baseline positron-emission tomography/computed tomography (PET/CT) in Hodgkin lymphoma (HL).
PATIENTS AND METHODS
A total of 162 consecutive patients with HL were retrospectively studied.
RESULTS
Disease was up-staged in 26 patients (16%) and down-staged in 9 (6%). However, treatment strategy was modified in only 10 patients (6% of total). Involved field radiotherapy was delineated according to PET/CT in 36/66 patients (59%). These treatment modifications did not significantly affect outcome. Moreover, three potent prognostic parameters were identified: the number of involved sites, maximum standardized uptake value (SUVmax), and the product of SUVmax and maximal largest lesion diameter, as a surrogate of total lesion glycolysis. All three significantly correlated with 5-year freedom from disease progression p=0.004, p=0.009 and p=0.04, respectively).
CONCLUSION
Baseline PET/CT findings may lead to treatment modification in <15% of patients with HL without a significant impact on outcome. Certain PET/CT parameters have potent prognostic significance.
目的
探讨基线正电子发射断层扫描/计算机断层扫描（PET/CT）对霍奇金淋巴瘤（HL）实际临床的影响。
患者与方法
对162例连续性HL患者进行回顾性研究。
结果
26例患者（16%）疾病分期上调，9例患者（6%）疾病分期下调。然而，仅10例患者（占总数的6%）治疗策略发生改变。66例患者中有36例（59%）根据PET/CT划定受累野放疗范围。这些治疗调整对预后无显著影响。此外，确定了三个有效的预后参数：受累部位数量、最大标准化摄取值（SUVmax）以及SUVmax与最大病灶直径的乘积，作为总病灶糖酵解的替代指标。这三个参数均与5年无疾病进展显著相关（p分别为0.004、0.009和0.04）。
结论
基线PET/CT检查结果可能使不到15%的HL患者治疗方案发生改变，且对预后无显著影响。某些PET/CT参数具有有效的预后意义。
Zotero 插件